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Abstract 1 
Short successive periods of muscle disuse, due to injury or illness, can contribute significantly to the loss 2 
of muscle mass with aging (sarcopenia). It has been suggested that increasing the protein content of the diet 3 
may be an effective dietary strategy to attenuate muscle disuse atrophy. We hypothesized that protein 4 
supplementation twice-daily would preserve muscle mass during a short period of limb immobilization. 5 
Twenty-three healthy, elderly (69±1 y) males were subjected to 5 days of one-legged knee immobilization 6 
by means of a full leg cast with (PRO group; n=11) or without (CON group; n=12) administration of a 7 
dietary protein supplement (20.7 g protein, 9.3 g carbohydrate, and 3.0 g fat) twice daily. Two days prior 8 
to and immediately after the immobilization period, single slice CT-scans of the quadriceps and single leg 9 
1-Repetition Maximum (1RM) strength tests were performed to assess muscle cross-sectional area (CSA) 10 
and leg muscle strength, respectively. Additionally, muscle biopsies were collected to assess muscle fiber 11 
characteristics, and mRNA and protein expression of selected genes. 12 
Immobilization decreased quadriceps CSA by 1.5±0.7% (P<0.05) and 2.0±0.6% (P<0.05), and muscle 13 
strength by 8.3±3.3% (P<0.05) and 9.3±1.6% (P<0.05) in the CON and PRO groups, respectively; without 14 
differences between groups. Skeletal muscle myostatin, myogenin, and MuRF1 mRNA expression 15 
increased following immobilization in both groups (P<0.05), while muscle MAFbx mRNA expression 16 
increased in the PRO group only (P<0.05). In conclusion, dietary protein supplementation (~20 g twice 17 
daily) does not attenuate muscle loss during short-term muscle disuse in healthy older men. Clinical trial 18 
registration: NCT01588808 19 
 20 
Abstract word count: 250 21 
22 
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Introduction 23 
A period of prolonged (i.e. several weeks) muscle disuse, due to illness or injury, can lead to substantial 24 
loss of skeletal muscle mass and strength in otherwise healthy individuals. The resulting negative health 25 
consequences, such as impaired functional capacity (1-3), decreased muscle strength (4), the onset of insulin 26 
resistance (5), and a decline in basal metabolic rate (6, 7), are of particular concern to elderly individuals, 27 
who are already functionally and/or metabolically compromised. Recently, we (8, 9) as well as others (10) 28 
have shown that even a few days of disuse can already lead to significant losses of muscle mass and strength 29 
in young and old men. These findings are of particular clinical relevance as hospitalization of elderly due 30 
to acute illness generally results in an average 5-7 day hospital stay (11). It has been hypothesized that such 31 
short successive periods of muscle disuse occurring throughout the lifespan may be instrumental in the 32 
progressive loss of muscle mass that occurs with aging (12, 13). 33 
Any substantial loss of skeletal muscle mass due to muscle disuse must be attributed to a chronic imbalance 34 
between muscle protein synthesis and breakdown rates. A decline in basal (post-absorptive) muscle protein 35 
synthesis rates has been reported following both bed-rest (14-16) as well as limb immobilization (17-19). 36 
Furthermore, recent work from our laboratory (20) as well as others (17, 21, 22) has shown that the muscle 37 
protein synthetic response to protein or amino acid administration becomes blunted following a period of 38 
disuse. Additionally, there is some indirect evidence that increases in muscle protein breakdown rates occur 39 
during the initial first few days of muscle disuse only (23-25). As such, it is now widely thought that 40 
declines in both post-absorptive and post-prandial muscle protein synthesis rates play the major causal role 41 
in the loss of muscle mass during a period of disuse (26, 27). Dietary protein intake stimulates muscle 42 
protein synthesis rates and inhibits muscle protein breakdown, and thereby allows net muscle protein 43 
accretion (28). Accordingly, it has been speculated that maintaining or even increasing dietary protein 44 
intake can attenuate muscle loss during a period of disuse (12, 27). In support, intervention studies have 45 
shown high-dose, essential amino acid supplementation to attenuate muscle loss during prolonged bed-rest 46 
in young (29-31) and elderly individuals (32). However, the potential for a practical dietary protein feeding 47 
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strategy to alleviate muscle loss during short-term disuse in the elderly population remains to be 48 
investigated. 49 
In the present study, we investigated our hypothesis that dietary protein supplementation attenuates muscle 50 
loss during a short period of muscle disuse in older men. To test this hypothesis, 23 healthy elderly men 51 
were selected to participate in a study during which they were subjected to 5 days of one-legged knee 52 
immobilization with or without dietary protein supplementation (~20 g protein twice daily). Muscle mass 53 
and strength were assessed prior to and immediately after immobilization, and muscle biopsy samples were 54 
collected to assess muscle fiber characteristics and associated myocellular signaling. 55 
56 
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Methods 57 
 58 
Subjects 59 
Twenty-three healthy elderly men (mean age 69±1 y) were included in the present study. Prior to inclusion, 60 
a general health questionnaire was filled in by the subjects and a routine medical screening was completed 61 
to exclude individuals with BMI below 18.5 or above 30 kg/m2; any back, knee or shoulder complaints that 62 
could interfere with the use of crutches; a (family) history of thrombosis; type 2 diabetes mellitus 63 
(determined by HbA1c values >7.0%); severe cardiac problems; or a history of performing prolonged 64 
resistance-type exercise in the six months preceding the start of the study. All subjects were informed on 65 
the nature and risks of the experiment before written informed consent was obtained. The present study was 66 
approved by the Medical Ethical Committee of Maastricht University Medical Centre+ in accordance with 67 
the Declaration of Helsinki. 68 
 69 
Experimental outline 70 
An overview of the experimental protocol is depicted in Figure 1. After inclusion into the study, subjects 71 
were randomly allocated to either the control (CON, n=12) or the protein (PRO, n=11) group. Both groups 72 
were subjected to five days of muscle disuse induced by way of a full leg cast. The immobilized leg was 73 
randomly allocated and counter-balanced between left and right. Two days prior to casting and directly 74 
after cast removal, a series of measurements was performed. Single slice computed tomography (CT) scans 75 
were performed at the mid-thigh of both legs, whole body dual energy x-ray absorptiometry (DEXA) scans 76 
were taken, a single muscle biopsy from the immobilized leg and venous blood sample were collected, and 77 
one-legged knee extension strength (1RM, one-repetition maximum) was assessed for both legs. 78 
 79 
Muscle mass and function tests 80 
Forty eight hours prior to, and directly after the casting period, subjects visited the laboratory for two 81 
identical test days (i.e. test days 1 and 2). During these test days, multiple measurements of muscle mass 82 
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and function were performed. Firstly, the anatomical cross-sectional area (CSA) of m. quadriceps femoris 83 
and whole thigh were assessed via a single slice computed tomography (CT) scan (Philips Brilliance 64, 84 
Philips Medical Systems, Best, The Netherlands) as done before (8). With subjects placed in a supine 85 
position, their legs extended and their feet secured, a 3 mm thick axial image was taken 15 cm proximal to 86 
the top of the patella. On test day 1 the exact scanning position was marked with semi-permanent ink for 87 
replication on test day 2. ImageJ software (version 1.46r, National Institute of Health, Bethesda, MD, USA) 88 
was used to analyze CT scan images for the cross-sectional area of all thigh muscles as well as the 89 
quadriceps muscle separately. Secondly, a DEXA scan (Hologic, Discovery A, QDR Series, Bradford, MA, 90 
USA) was used to determine body composition and bone mineral content. Leg lean mass was determined 91 
using the system’s software package Apex version 2.3. Maximal muscle strength was determined for each 92 
leg individually by 1RM strength tests on a leg extension machine (Technogym, Rotterdam, the 93 
Netherlands) as done before (8, 33). 94 
 95 
Blood and muscle sampling 96 
Fasting venous blood samples were collected for determination of basal plasma glucose and insulin 97 
concentrations on test day 1 and 2. Blood (10 mL) was collected in EDTA-containing tubes and 98 
immediately centrifuged at 1,000g for 10 min at 4°C. Aliquots of plasma were snap frozen in liquid nitrogen 99 
and stored at -80°C until further analysis. Plasma glucose, free fatty acids, and triglyceride concentrations  100 
were analyzed with a ABX Pentra 400 analyzer (Horiba Diagnostics, Montpellier, France) with test kits 101 
from ABX Diagnostics (Montpellier, France), whereas plasma insulin concentrations were determined by 102 
radioimmunoassay (Millipore, ref. HI-14K , Billerica, MA, USA). Plasma amino acid concentrations were 103 
measured using ultra-performance liquid chromatography tandem mass spectrometry as described 104 
previously (34). 105 
Muscle biopsies were taken from m. vastus lateralis of the immobilized leg prior to casting and immediately 106 
after cast removal, prior to performing any weight bearing activities. Biopsies were taken at the same time 107 
(08.30 AM) in the morning after an overnight fast and the same standardized meal was provided the evening 108 
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prior to muscle biopsy collection. Percutaneous muscle biopsies were taken from m. vastus lateralis with 109 
the Bergstrom technique, approximately 15 cm above the patella. The collected muscle was freed from any 110 
visible non-muscle tissue, processed immediately, and stored at -80°C until further analysis. 111 
 112 
Leg immobilization 113 
Two days after performing test day 1, at 8:00 in the morning, a full leg cast (randomized and 114 
counterbalanced for left and right leg) was applied in the casting room of the Academic Hospital in 115 
Maastricht. This marked the start of the 5 day immobilization period that always contained 3 week days 116 
and 2 weekend days. The cast extended from ~5 cm above the ankle until ~25 cm above the patella. A ~30 117 
degree angle of flexion of the knee joint was established in order to prevent subjects from performing 118 
weight-bearing activities with the immobilized leg. Subjects received crutches and were instructed on the 119 
correct usage before being provided with transportation home. The cast was removed at 8:00 on the morning 120 
of test day 2, after exactly 5 days of immobilization. 121 
 122 
Protein supplementation 123 
Subjects were randomly allocated to the group receiving a high whey protein leucine-enriched oral 124 
nutritional supplement (PRO) or the control group receiving no supplement (CON). Subjects allocated to 125 
the PRO group consumed the first drink in the laboratory on the morning of casting and were instructed to 126 
consume one drink directly after breakfast and one drink immediately prior to sleep on each day during 127 
immobilization (i.e. twice-daily, 10 drinks in total). Each drink provided 635 kJ, 21 g protein, 9 g 128 
carbohydrates, 3 g fat, and a mixture of vitamins, minerals and fibers. Supplemental Table 1 depicts the 129 
composition of the study product. 130 
 131 
Dietary intake 132 
Standardized meals, containing 2.9 MJ and providing 51 Energy% (En%) as carbohydrate, 32 En% as fat, 133 
and 17 En% as protein, were consumed on the evening prior to both test days. Weighted dietary intake 134 
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records were completed by the subjects for the 5 day duration of the immobilization period as well as on a 135 
separate consecutive 5 day occasion either before or after (randomly allocated to avoid recording bias) the 136 
immobilization period. The same 5 days of the week were selected for both recording periods. DieetInzicht 137 
software (35), based on the NEVO table 2011, was used to analyze dietary intake records. 138 
 139 
Muscle analysis 140 
Muscle samples were freed from any visible non-muscle tissue and separated into two sections. The first 141 
part (~30 mg) was imbedded in Tissue-Tek (Sakura Finetek, Zoeterwoude, the Netherlands), frozen on 142 
liquid nitrogen cooled isopentane and used to determine muscle fiber-type specific cross-sectional area 143 
(CSA) and satellite cell content as done previously (8). The second part (~15 mg) was snap frozen in liquid 144 
nitrogen and used for real time-PCR analysis to determine mRNA expression of selected genes as described 145 
before (8, 20). A detailed overview of the muscle analyses is presented in the online supporting material. 146 
 147 
Statistics 148 
All data are expressed as mean±SEM. Baseline values between groups were compared by means of an 149 
independent samples t-test. Pre- versus post-immobilization data were analyzed using Repeated Measures 150 
ANOVA with treatment (CON vs PRO) as between-subjects factor and time (pre- vs post-immobilization) 151 
as within-subjects factor. Fiber type (type I vs type II) was added to the test as a within-subjects factor when 152 
performing the statistical analyses for the muscle data. In case of a significant main effect, paired-samples 153 
t tests were executed to determine time effects within treatment groups or within fiber types, and 154 
independent-samples t tests were performed to determine group differences in pre- and post-immobilization 155 
values. When a significant main effect was detected, Bonferroni’s post hoc test was applied to locate the 156 
differences. A P-value of <0.05 was used to determine statistical significance. All data were analyzed using 157 
SPSS version 20.0 (SPSS Inc., Chicago, IL, USA).  158 
 10 
 
Results 159 
 160 
Subjects 161 
Subjects’ characteristics are provided in Table 1. No baseline differences between the control (CON) and 162 
protein (PRO) groups were observed for age, height, weight, BMI, glucose, insulin, HOMA, or HbA1c 163 
levels at baseline. Glucose, insulin, and HOMA were measured pre- and post-intervention, and did not 164 
change over time in either group. 165 
 166 
Muscle mass and strength 167 
Quadriceps muscle cross-sectional area (CSA) is displayed in Figure 2A. At baseline, no differences were 168 
observed in quadriceps or whole leg muscle CSA between groups (P>0.05 for both parameters). Five days 169 
of immobilization caused significant muscle atrophy of the quadriceps (time effect, P<0.001; see Figure 170 
2A) and the whole leg (time effect, P<0.05; from 13.3±5.4 to 13.2±5.3 cm2 (-0.7±0.6%) in CON and from 171 
12.6±4.2 to 12.4±4.6 cm2 (-1.6±0.6%) in PRO) with no differences between groups (P-interaction>0.05 for 172 
both parameters). Immobilization did not affect whole-body or leg lean mass in either group (data not 173 
shown; both P>0.05). Leg muscle strength data are presented in Figure 2B. Maximal leg muscle strength 174 
had decreased following immobilization in the CON and PRO group (time effect, P<0.001), with no 175 
differences between groups (P-interaction>0.05). 176 
 177 
Dietary intake 178 
Table 2 shows data for subjects’ habitual diet for 5 days under free living conditions and during the 5 day 179 
immobilization period. No differences in habitual diet were observed between groups (all measured 180 
parameters P>0.05). Habitual diet did not change due to immobilization in the CON group (P>0.05), 181 
whereas in the PRO group, twice-daily ingestion of the protein drink significantly increased protein intake 182 
(expressed as g·day-1, g·kg-1·day-1, and En%) compared with baseline (P<0.05) and the CON group 183 
(P<0.05). Habitual protein intake averaged 1.1 g·kg-1·day-1 and was increased to 1.6 g·kg-1·day-1 during the 184 
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immobilization period in the PRO group. Energy intake in the PRO group was maintained during 185 
immobilization; a relatively higher amount of energy was received from protein, at the expense of energy 186 
from fat (P<0.05). 187 
 188 
Plasma analyses 189 
Plasma amino acid concentrations (Supplemental Table 2) were increased in both groups for alanine, 190 
cysteine, phenylalanine, threonine, and tryptophan (all P<0.05). For valine (P-interaction<0.05), an 191 
increase following immobilization was observed in the PRO group only (P<0.05). All other measured 192 
amino acids were not changed following immobilization (all P>0.05). Immobilization, with or without 193 
protein supplementation, did not influence plasma free fatty acid (CON: from 384±33 to 354±33 μmol/L; 194 
PRO: from 446±48 to 404±46 μmol/L) or triglyceride (CON: from 1190±210 to 1270±92 μmol/L; PRO: 195 
from 968±88 to 1110±118 μmol/L) concentrations (both P>0.05). 196 
 197 
Muscle fiber characteristics 198 
Muscle fiber characteristics are displayed in Table 3. At baseline, no differences between groups were 199 
observed for any of the variables. No measurable decline in muscle fiber CSA was observed following 200 
immobilization in either group (P>0.05). Although no changes in myonuclear content were observed 201 
following immobilization (P>0.05), myonuclear domain size decreased in both fiber types in both CON 202 
and PRO (time effect, P<0.05). At baseline, satellite cell (SC) content expressed per muscle fiber, per 203 
millimetre squared, and as a percentage of the total number of myonuclei was higher in type I compared 204 
with type II fibers (P<0.05 for all three parameters). No changes over time or differences between groups 205 
were observed (P>0.05). 206 
 207 
mRNA expression 208 
Figure 3 and Supplemental Figure 1 display the skeletal muscle mRNA expression of the selected genes 209 
of interest. Muscle mRNA expression of myostatin (Figure 3A) and myogenin (Figure 3C) increased 210 
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following immobilization in both groups (P<0.05), whereas myoD (Figure 3B) tended towards an increase 211 
in both groups (P=0.07). MAFBx mRNA expression (Figure 3D) showed a significant time*treatment 212 
interaction (P<0.05) with a significant increase only detected in the PRO group (P<0.05) following 213 
immobilization. Muscle MuRF1 mRNA (Figure 3E) significantly increased in both groups (time effect, 214 
P<0.01). There was a trend for an interaction effect (P=0.07) such that MuRF1 mRNA expression was 215 
increased to a greater extent in PRO (P<0.05) compared with CON (P>0.05). For the mRNA expression of 216 
both amino acid transporters LAT1 (Supplemental Figure 1D) and PAT1 (Supplemental Figure 1E), a 217 
significant time effect was found (P<0.01 for both genes) such that expression was upregulated following 218 
immobilization in both groups. All other genes showed no significant changes between or within groups.  219 
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Discussion 220 
In the present study, we demonstrate that merely 5 days of one-legged knee immobilization leads to 221 
substantial skeletal muscle mass and strength loss in healthy, elderly men. Increasing dietary protein intake 222 
by supplementing ~20 g protein twice-daily did not attenuate the loss of muscle mass or strength during 5 223 
days of muscle disuse in older males. 224 
A period of prolonged muscle disuse and the associated muscle atrophy causes numerous negative health 225 
consequences (1, 2, 4, 6), and the occurrence of successive periods of muscle disuse likely represents a key 226 
factor responsible for the loss of muscle mass during the later decades of our lifespan (13). In the present 227 
study, we report that only 5 days of muscle disuse already leads to substantial loss of muscle mass (-228 
1.5±0.7%; Figure 2A) and strength (-8.3±3.3%; Figure 2B) in older individuals. These data are in line with 229 
recent data from our group in which we observed similar muscle mass and strength losses in younger 230 
individuals (8). Furthermore, Suetta et al. reported significant muscle fiber atrophy after 4 days of 231 
immobilization in both young and older individuals (10). The rapid muscle atrophy observed in our older 232 
subjects after merely 5 days of leg immobilization is of important clinical significance, as successive short 233 
periods of muscle disuse due to illness or injury are highly prevalent during the later stages of our lifespan 234 
(36). In line, the average length of hospitalization for elderly patients admitted with acute illness is 5–7 235 
days (11). The observed muscle loss is of particular relevance as the older population has difficulty to regain 236 
skeletal muscle mass and strength following a period of disuse (37). Even when applying rehabilitative 237 
resistance-type exercise training after a period of disuse, muscle mass does not seem to be restored after 4 238 
weeks of intense supervised training (37). For these reasons, it is presently believed that the impact of short 239 
successive episodes of muscle disuse may be of key relevance in the development of sarcopenia (13). 240 
Practical and effective interventional strategies are needed to prevent or attenuate muscle mass and strength 241 
loss during short periods of muscle disuse in healthy elderly as well as more clinically compromised 242 
subpopulations. It has been proposed that simply increasing the protein content of the diet may alleviate the 243 
loss of muscle tissue during a period of disuse (12, 27). Indeed, studies focusing on mimicking prolonged 244 
hospitalization (i.e. >2-3 weeks bed-rest under tightly controlled dietary conditions) have shown that 245 
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supplementation with high doses of crystalline essential amino acids (~50 g, equivalent to ~100-150 g intact 246 
protein) attenuates the loss of muscle mass (29-31). Given the clinical relevance of short, successive periods 247 
of muscle disuse, we assessed the efficacy of a more practical and feasible dietary strategy to attenuate 248 
muscle loss during a short period of limb immobilization under free living conditions. Increasing dietary 249 
protein intake from 1.1 to 1.6 g·kg body weight-1·day-1 did not rescue the loss of muscle mass or strength 250 
observed during a 5 day period of leg immobilization (Figure 2). The apparent discrepancy between the 251 
outcome of the present study and previous work in prolonged bed rest studies may be attributed to 252 
differences in protein intake in the control group. In the present study the control group retained normal 253 
habitual energy and protein intake (1.1 g·kg-1·day-1) whereas the protein group received additional 254 
supplementation (1.6 g·kg-1·day-1). In contrast, in previous bed rest studies that show benefits of amino acid 255 
supplementation on muscle mass maintenance, the control groups generally consumed dietary protein at a 256 
level no higher than 0.8 g·kg-1·day-1 (29-31). Consequently, we speculate that maintaining dietary protein 257 
intake is required to prevent muscle loss during disuse, but that increasing dietary protein intake above 258 
habitual levels does not further alleviate muscle loss during disuse (38, 39). This would be of particular 259 
relevance in institutionalized or hospitalized elderly who are unable to maintain habitual dietary protein 260 
consumption during more prolonged periods of muscle disuse due to illness or injury. Additional 261 
considerations of the present nutritional intervention include the type and timing of protein administered. 262 
We selected whey protein in the present study as we have previously shown it leads to greater post-prandial 263 
muscle protein accretion compared with casein protein in healthy elderly men (40). We chose to supplement 264 
volunteers at breakfast time since we have previously shown that community dwelling elderly individuals 265 
generally consume inadequate amounts of protein at breakfast (41). Specifically, the supplement was 266 
consumed directly after breakfast to avoid volunteers compensating for the supplement by consuming less 267 
breakfast and therefore ensuring adequate protein was consumed. This was achieved given that the PRO 268 
group consumed (36±2 g at this meal compared to the CON group who only consumed 13±1 g, the latter 269 
being an amount insufficient to properly stimulate muscle protein synthesis rates (42). We opted to deliver 270 
the second supplement immediately prior to sleep, since we have recently shown that such a strategy 271 
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effectively stimulates overnight muscle protein synthesis rates (43). However, it is also true that these 272 
beneficial effects on nocturnal muscle protein synthesis were obtained with the ingestion (or intragastric 273 
administration) of large amounts of casein protein, to ensure a more sustained hyperaminoacidemia 274 
throughout the night (44). Accordingly, it could be speculated that future nutritional strategies aimed at 275 
attenuating muscle disuse atrophy may wish to consider incorporating large boluses of casein as a pre-276 
bedtime meal. In contrast, it could also be hypothesized that ingestion of a large bolus of dietary protein 277 
prior to sleep increases both muscle protein synthesis and breakdown rates, without net muscle protein 278 
accretion (45). Though previous work has shown improvements in overnight whole-body protein balance 279 
following protein administration in healthy older men (43) and in young adults during overnight recovery 280 
from exercise (46), we cannot exclude that such improvements in overnight protein balance may not occur 281 
in a setting of muscle disuse.  282 
Besides assessing the impact of protein supplementation on muscle mass and strength during short-term 283 
disuse, we wished to gain insight into the underlying myocellular mechanisms involved in muscle disuse 284 
atrophy and/or muscle mass maintenance. Muscle loss during short-term muscle disuse is thought to be, at 285 
least partly, mediated by accelerated rates of muscle protein breakdown (13). Myostatin is known as a 286 
negative regulator of muscle growth in vivo (47), and acts through multiple pathways including the 287 
stimulation of muscle protein breakdown (48). Consistent with this role, we observed increases in myostatin 288 
mRNA expression (Figure 3) and in markers of muscle protein breakdown (i.e. increased gene expression 289 
of MAFBx and MuRF1; Figure 3). This is in line with previous findings (10) and our own work in young 290 
men (8, 9), and supportive of a role for muscle protein breakdown in short-term muscle atrophy, possibly 291 
mediated through increased myostatin transcription. Given the lack of effect of protein supplementation on 292 
muscle mass in the present study, it is not surprising that we observed no attenuation of the rise in myostatin 293 
and markers of proteolysis. In fact, we actually observed that MAFBx and MuRF1 gene expression 294 
increased to a greater extent in the PRO group (Figure 3), supporting the idea that increasing dietary protein 295 
intake beyond the habitual dietary protein intake level may strongly stimulate overall protein turnover rates. 296 
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 Myostatin is also reported to regulate muscle size by acting via the inhibition of myogenesis through its 297 
inhibitory action on the myogenic regulatory factors (49). However, in line with our previous work (8, 50), 298 
we report that the disuse-induced increase in myostatin expression does not coincide with impaired 299 
expression of the myogenic regulatory factors (i.e. MyoD and myogenin, Figure 3). Moreover, no 300 
alterations in muscle satellite cell content were observed, suggesting that the mechanisms underlying short-301 
term disuse atrophy do not require alterations in myogenesis or satellite cell content. Recent data have 302 
suggested that the expression of specific amino acid transporters within skeletal muscle provide a site of 303 
regulation for muscle protein synthesis (51). As such, we analyzed the gene expression of Large Neutral 304 
Amino Acid Transporter 1 (LAT1/SLC) and Proton-coupled amino acid transporter 1 (PAT1) which are 305 
thought to be the key transporters facilitating intramuscular transport of BCAAs particularly in response to 306 
nutrition (52). Interestingly, LAT1 and PAT1 mRNA expression (Supplemental Figure 1) increased 307 
following immobilization in both groups, possibly indicating a compensatory mechanism by which 308 
atrophying muscle attempts to ‘scavenge’ circulating amino acids as a substrate for muscle protein 309 
synthesis. 310 
In the present study we show that protein supplementation on top of a diet containing ample protein (1.1 311 
g·kg-1·day-1) does not alleviate muscle loss during short-term single leg disuse. This shows that besides 312 
maintaining dietary protein intake, other strategies are warranted to help maintain muscle mass. Where 313 
possible, performing some degree of exercise should be considered during disuse (39). In conditions where 314 
exercise is not feasible due to injury or illness, low-volume physical activity (53) or even exercise surrogates 315 
(8) could be suggested. Furthermore, other nutritional compounds, such as creatine or omega-3 fatty acids, 316 
may support muscle maintenance during disuse (27). An often under-appreciated consideration is how 317 
dietary strategies could support rehabilitation following a period of disuse. This area has been 318 
comparatively under studied (54-57) but, given the opportunity to combine nutrition with re-ambulation 319 
and/or physical exercise, future research should address how dietary protein and/or other nutritional 320 
strategies could best be used to facilitate the rapid and complete restoration of muscle mass following a 321 
period of disuse.  322 
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In short, we conclude that short-term muscle disuse results in a substantial decline in both muscle mass and 323 
strength in older individuals. Increasing dietary protein intake during short-term muscle disuse on top of a 324 
diet providing >1.0 g·kg-1·day-1 does not alleviate muscle disuse atrophy in healthy, elderly men. 325 
326 
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Tables 
 
Table 1: Subjects’ characteristics of healthy older men in the control (CON) and protein supplemented 
(PRO) groups1,2,3 
 CON (n=12) PRO (n=11) 
Age, y 70 ± 1 68 ± 1 
Body mass, kg 82.9 ± 3.0 79.6 ± 2.4 
Height, m 1.74 ± 0.02 1.74 ± 0.02 
BMI, kg/m2 27.3 ± 0.6 26.4 ± 0.8 
Leg volume, L 
Plasma glucose, mmol/L 
Plasma insulin, uU/mL 
HOMA-index 
7.96 ± 0.28 
5.6 ± 0.1 
11.7 ± 1.4 
3.0 ± 0.4 
7.90 ± 0.35 
5.7 ± 0.1 
9.9 ± 1.0 
2.6 ± 0.3 
Glycated hemoglobin, % 5.4 ± 0.1 5.7 ± 0.1 
Glycated hemoglobin, mmol/mol 35.9 ± 1.2 38.4 ± 1.3 
1 Values are means±SEM, n=23. 
2 Abbreviations: HOMA-index, Homeostatic Model Assessment Index. 
3 No differences were observed between groups (P>0.05 for all variables).
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Table 2: Dietary intake of healthy elderly subjects under free-living conditions and during a 5-day period of leg immobilization, with (PRO) or 
without (CON) supplementation.1,2,3 
Variable CON (n=12) PRO (n=11) 
 Free living Immobilization Free living Immobilization 
Energy intake, MJ · day-1 8.82 ± 0.62 9.03 ± 0.46 8.73 ± 0.54 9.50 ± 0.49 
Protein intake, g · day-1 85 ± 9 86 ± 4 90 ± 4 125 ± 6 * 
Protein, g · kg-1 · day-1 1.04 ± 0.12 1.05 ± 0.06 1.14 ± 0.07 1.60 ± 0.11 * 
Protein, En% 16.7 ± 1.2 16.4 ± 0.7 18.0 ± 0.9 22.9 ± 1.0 * 
Fat, En% 31.6 ± 1.3 32.9 ± 2.3 29.5 ± 1.8 25.8 ± 1.2 * 
Carbohydrate, En% 51.7 ± 2.0 50.6 ± 2.1 52.5 ± 2.1 51.3 ± 1.5 
1 Data represent means±SEM, n=23. 
2 Data in the PRO group are expressed including twice-daily intake of the protein supplement. 
3 * Significantly different from free living value (P<0.05)
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Table 3: Muscle fiber characteristics of healthy elderly individuals before (pre) and after (post) 5 days of leg immobilization, with (PRO) or without 
(CON) supplementation.1,2,3,4 
  CON (n=12) PRO (n=11) 
 Fiber type Pre Post Pre Post 
Muscle fiber CSA, µm2 I 5654 ± 391 5037 ± 487 5646 ± 469 5370 ± 379 
 II 5592 ± 564 5000 ± 525 5131 ± 390 5027 ± 356 
Fiber, % I 49 ± 3 44 ± 3 48 ± 5 48 ± 5 
 II 51 ± 3 56 ± 3 52 ± 5 52 ± 5 
Fiber, area % I 50 ± 4 45 ± 3 51 ± 5 49 ± 6 
 II 50 ± 4 55 ± 3 49 ± 5 51 ± 6 
Nuclei, n/fiber I 2.8 ± 0.1 2.9 ± 0.3 2.8 ± 0.2 2.9 ± 0.2 
 II 2.8 ± 0.1 2.8 ± 0.2 2.8 ± 0.2 2.8 ± 0.2 
Myonuclear domain, µm2 I 2026 ± 86 1716 ± 106 * 2035 ± 89 1914 ± 97 * 
 II 2072 ± 112 1770 ± 126 * 1843 ± 111 1791 ± 112 * 
SC, n/fiber I 0.101 ± 0.014 0.091 ± 0.013 0.099 ± 0.010 0.099 ± 0.007 
 II 0.056 ± 0.008 # 0.055 ± 0.009 # 0.062 ± 0.006 # 0.060 ± 0.006 # 
SC, n/mm2 I 18.1 ± 2.5 18.0 ± 2.3 17.7 ± 2.1 19.1 ± 1.6 
 II 10.1 ± 1.5 # 10.3 ± 1.4 # 11.8 ± 1.1 # 12.7 ± 1.6 # 
SC, n/myonuclei, % I 3.6 ± 0.4 3.3 ± 0.5 3.7 ± 0.5 3.6 ± 0.3 
 II 1.9 ± 0.2 # 2.0 ± 0.3 # 2.2 ± 0.2 # 2.2 ± 0.2 # 
1 Data represent means±SEM, n=23. 
2Abbreviations: CSA, Cross-sectional area; SC, satellite cell; SC, n/myonuclei (%), the number of SCs as a percentage of the total number of 
myonuclei (i.e. number of myonuclei + number of SCs). 
3 # Significantly different from values in type I fiber (P<0.05) 
4 * Significantly different from pre-immobilization values (P<0.05)
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Figure legends 
 
Figure 1: Outline of the experimental protocol. Two groups of healthy elderly males were included to 
undergo 5 days of one-legged knee-immobilization, with (PRO; n=11) or without (CON; n=12) protein 
supplementation (~20 g protein twice daily). 
 
Figure 2: A Cross-sectional area (CSA) of m. quadriceps femoris in healthy elderly participants in the CON 
(n=12) and PRO (n=11) groups, measured by single-slice CT scan 48h prior to and immediately following 
5 days of leg immobilization. B Leg muscle strength as measured by 1RM, in both the CON and PRO 
group. Data are expressed as means±SEM. *P<0.05; significantly different when compared with pre-
immobilization values. 
 
Figure 3: Skeletal muscle mRNA expression of selected genes involved in myogenesis (A-B-C) and 
muscle proteolysis (D-E-F), measured 48h prior to and immediately following 5 days of one-legged knee 
immobilization in healthy elderly men in the CON (n=12) and PRO (n=11) group. *P<0.05; significantly 
different when compared with pre-immobilization values. Data are expressed as means±SEM. 
Abbreviations: MAFbx, Muscle Atrophy F-box; MuRF1, Muscle RING-finger protein-1; FOXO1, 
Forkhead box protein O1. 
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Supplemental Table 1: Composition of the study product1,2 
Component Unit PRO 
Energy kcal / kJ 150 / 635 
     Protein % 55 
     Carbohydrates % 25 
     Fat % 18 
     Fiber % 2 
Protein   
     Total g 20.7 
     Total EAA g 10.6 
     Total leucine g 2.8 
     Total phenylalanine g 0.6 
Carbohydrates   
     Total g 9.4 
     Sugars g 4.2 
Fat   
     Total g 3.0 
     Saturated g 0.8 
Fiber   
     Total g 1.3 
     Soluble g 1.3 
Minerals   
     Sodium mg 150 
     Potassium mg 279 
     Chloride mg 70 
     Calcium mg 500 
     Phosphorus mg 250 
     Magnesium mg 37 
Trace elements   
     Iron mg 2.4 
     Zinc mg 2.2 
     Copper μg 270 
     Manganese mg 0.50 
     Fluoride mg 0.15 
     Molybdenum μg 15 
     Selenium μg 15 
     Chromium μg 7.5 
     Iodine μg 20 
Vitamins   
     Vitamin A μg-RE 152 
     Cholecalciferol μg 20 
     Vitamin E mg α-TE 7.5 
     Phylloquinone μg 12 
     Thiamin mg 0.23 
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Component Unit PRO 
     Riboflavin mg 0.25 
     Niacin mg NE 8.8 
     Pantothenic acid mg 0.81 
     Vitamin B6 mg 0.76 
     Folic acid μg 203 
     Vitamin B12 μg 3.0 
     Biotin μg 6.1 
     Vitamin C μg 32 
Extra additions   
     Carotenoids mg 0.30 
     Choline mg 56 
1 Data are presented as mean values, n=23 
2 Abbreviations used: EAA, essential amino acid; NE, niacin equivalents; RE, retinol equivalents; α-TE, α-
tocopherol equivalents 
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Muscle analyses 
Muscle samples that were mounted and frozen in Tissue-Tek were cut into 5µm thick cryosections using a 
cryostat at -20°C. Samples were carefully aligned for cross-sectional fiber analyses. Pre and post 
immobilization samples from one PRO and one CON subject were mounted together on uncoated, pre-
cleaned glass slides. All biopsies were stained for muscle fiber type (FT) and satellite cell (SC) content. At 
the start of the staining procedure, glass slides were incubated with primary antibodies against myosin 
heavy chain (MHC)-I (A4.840, dilution 1:25, Developmental Studies Hybridoma Bank, Iowa City, IA), 
laminin (polyclonal rabbit anti-laminin, dilution 1:50; Sigma, Zwijndrecht, the Netherlands) and CD56 
(dilution 1:40; BD Biosciences, San Jose, CA). CD56 has been used in previous research by ourselves (33, 
58, 59) and others (60) for determination of SC content in human skeletal muscle. After washing, slides 
were incubated with the appropriate secondary antibodies: goat anti-rabbit IgG AlexaFluor647, goat anti-
mouse IgM AlexaFluor555, and Streptavidin Alexa 488 (dilution 1:400, 1:500, and 1:200, respectively; 
Molecular Probes, Invitrogen, Breda, the Netherlands). Nuclei were stained with 4,6-diamidino-2-
phenylindole (DAPI, 0.238 µM; Molecular Probes). All incubations steps were done at room temperature. 
Both primary and secondary antibodies were diluted in 0.1% Bovine Serum Albumin (BSA) in 0.1% 
Tween- phosphate-buffered saline (PBS). The staining procedure was done as follows. After slides were 
fixated in acetone for 5 min, slides were air dried and incubated for 30 min with 3% BSA in 0.1% Tween-
PBS. After a 5 min washing step with PBS, slides were incubated with CD56 in 0.1% BSA in 0.1% Tween-
PBS for 2 h. Afterwards slides were washed (standard washing protocol: 5 min 0.1% Tween-PBS, 2 x 5 
min PBS) and incubated with goat anti-mouse Biotin (dilution 1:133, Vector Laboratories, Inc., 
Burlingame, CA) for 60 min. After washing, slides were incubated with Steptavidin for 30 min. Thereafter, 
slides were washed and incubated with primary antibodies against MHC-1 and laminin for 30 min. Slides 
were washed and the appropriate secondary antibodies were applied, diluted together with DAPI. After a 
final washing step, all slides were mounted with cover glasses using Mowiol (Calbiochem, Amsterdam, the 
Netherlands). Staining procedures resulted in nuclei stained in blue, CD56 in green, MHC-I in red, and 
laminin in far-red. Images were visualized and automatically captured at 10x magnification with a 
fluorescent microscope equipped with an automatic stage (IX81 motorised inverted microscope, Olympus, 
Hamburg, Germany) and EXi Aqua CCD camera (QImaging, Surrey, BC, Canada). Image acquisition was 
performed by Micro-Manager 1.4 software as done before (50). Analysis of the recorded images was 
performed by an investigator blinded to subject coding. To assess fiber circularity, form factors were 
calculated by using the following formula: (4π·CSA)/(perimeter)2. Fiber circularity did not change over 
time or between groups. Mean numbers of 148±12 and 151±12 fibers were analyzed in pre- and post-
immobilization samples, respectively. 
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The part of the muscle that was directly frozen in liquid nitrogen was used to determine mRNA expression 
of several genes of interest. Total RNA was isolated by using Tri Reagent (Sigma-Aldrich) on 10-20 mg of 
frozen muscle, according to the manufacturer’s protocol. Quantification of total RNA was carried out 
spectrophotometrically at 260 nm (NanoDrop ND-1000 Spectrophotometer, Thermo Fisher Scientific, 
USA), and RNA purity was determined as the ratio of readings at 260/280 nm. Subsequently, first strand 
cDNA was synthesized from 1 μg RNA sample using random primers (Promega) and PowerScript Reverse 
Transcriptase (AppliedBiosystems, USA). Taqman PCR was carried out using an ABI Prism 7000 sequence 
detector (AppliedBiosystems, USA), with 2 μL of cDNA, 18 μl.L-1 of each primer, 5 μl.L-1 probe, and 
Universal Taqman 2 × PCR mastermix (Eurogentec) in a final volume of 25 μL. Each sample was run in 
duplicate, in duplex reactions, with a separate standard curve included for each gene (serial dilutions of 
cDNA synthesized in parallel with the study sample). 18S was used as a housekeeping gene as an internal 
control, and similarly to previous human immobilization studies (8, 20) it seemed unaffected by treatment 
(i.e. mean Ct values did not change over time in each of the intervention groups; data not shown). Taqman 
primer/probe sets (Applied Biosystems, Foster City, USA) were obtained for the following genes of 
interest: mammalian target of rapamycin (mTOR), P70S6 kinase (P70S6K), myogenic factor 4 (myogenin), 
MyoD, myostatin, Atrogin-1/Muscle Atrophy F-box (MAFbx), Muscle RING-finger protein-1 (MuRF1), 
Forkhead box protein O1 (FOXO1), Focal Adhesion Kinase (FAK), large neutral amino acid transporter 1 
(LAT1) and Proton-coupled amino acid transporter 1 (PAT1). All genes of interest were labelled with the 
fluorescent reporter FAM. The thermal cycling conditions used were: 2 min at 50oC, 10 min at 95oC, 
followed by 40 cycles at 95°C for 15 s and 60°C for 1 min. Ct values of the genes of interest were 
normalized to Ct values of the housekeeping gene, and final results were calculated as relative expression 
against the standard curve. 
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Supplemental Table 2: Plasma amino acid concentrations measured 48h prior to and immediately 
following 5 days of one-legged knee immobilization in healthy elderly men with (PRO; n=11) or without 
(CON; n=12) twice-daily protein supplementation.1,2 
 CON (n=12) PRO (n=11) 
 Pre Post Pre Post 
 μmol/L μmol/L μmol/L μmol/L 
α-aminobutyric acid  30 ± 4 25 ± 2 27 ± 2 30 ± 4 
Alanine 393 ± 36 485 ± 36 * 379 ±25 423 ± 22 * 
Arginine 88 ± 5 90 ± 4 84 ± 3 81 ± 4 
Asparagine 47 ± 2 47 ± 2 45 ± 2 45 ± 2 
Aspartic acid 5 ± 1 5 ± 1 4 ± 1 4 ± 1 
Citrulline 39 ± 3 36 ± 2 35 ± 1 38 ± 3 
Cysteine 42 ± 3 46 ± 2 * 44 ± 2 50 ± 2 * 
Glutamic acid 69 ± 10 68 ± 7 58 ± 9 59 ± 9 
Glutamine 605 ± 29 622 ± 27 575 ± 39 540 ± 31 
Glycine 217 ± 11 237 ± 12 204 ± 10 194 ± 13 
Histidine 86 ± 5 86 ± 2 83 ± 4 84 ± 3 
Isoleucine 70 ± 5 73 ± 4 66 ± 4 76 ± 8 
Leucine 138 ± 8 137 ± 5 128 ± 7 154 ± 16 
Lysine 190 ± 10 191 ± 7 177 ± 9 212 ± 14 
Methionine 28 ± 2 29 ± 1 27 ± 1 30 ± 2 
Ornithine 60 ± 4 62 ± 3 58 ± 4 60 ± 4 
Phenylalanine 59 ± 3 60 ± 2 * 56 ± 3 64 ± 2 * 
Proline 218 ± 27 223 ± 22 169 ± 14 192 ± 12 
Serine 90 ± 6 93 ± 5 85 ± 5 89 ± 7 
Taurine 81 ± 8 89 ± 6 96 ± 10 82 ± 7 
Threonine 129 ± 7 135 ± 8 * 120 ± 7 154 ± 15 * 
Tryptophan 56 ± 4 59 ± 3 * 53 ± 3 62 ± 4 * 
Tyrosine 67 ± 4 69 ± 3 65 ± 4 71 ± 3 
Valine 261 ± 17 259 ± 9 240 ± 12 288 ± 19 * 
1 Data are presented as means ± SEM, n=23. 
2 * Significantly different from pre-immobilization value (P<0.05). 
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Supplemental Figure 1
 
Supplemental Figure 1: mRNA expression of anabolic genes of interest in the CON (n=12) and PRO 
(n=11) group 48h prior to and immediately following 5 days of leg immobilization. *P<0.05; significantly 
different when compared with pre-immobilization values. Data are expressed as means±SEM, n=23. 
Abbreviations: FAK, Focal Adhesion Kinase; LAT1, large neutral amino acid transporter; mTOR, 
mammalian target of rapamycin; PAT1, proton-coupled amino acid transporter 1; P70S6K, P70S6 kinase. 
 
No significant time*treatment nor time effects were found for mTOR (Supplemental Figure 1A), P706SK 
(Supplemental Figure 1B), and FAK (Supplemental Figure 1C: all P>0.05).  
 
 
